D3572
Dipeptidyl Peptidase IV Inhibitor IV
别名:
(S)-1-(4-Methyl-1-(2-pyrimidinyl)-4-piperidylamino)acetyl-2-pyrrolidinecarbonitrile, K579
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C17H24N6O
分子量:
328.41
NACRES:
NA.77
UNSPSC Code:
12352202
Assay:
≥97% (HPLC)
General description
Dipeptidyl Peptidase IV Inhibitor IV, also known as K579 ((S)-1-[4-methyl-1-(2-pyrimidinyl)-4-piperidylamino]acetyl-2-pyrrolidinecarbonitrile), is orally available. It has a formula weight of 339.39 g/mol.
Biochem/physiol Actions
Dipeptidyl peptidase IV (DPP IV) is a key enzyme involved in the regulation of incretin hormone levels in the gastrointestinal tract. Incretin hormones, such as glucagon like peptide (GLP-1) and glucose-dependent insulinotropic hormone (GIP) / gastric inhibitory peptide, cause the glucose stimulated release of insulin. This allows the endocrine system to preemptively stimulate release insulin in response to ingestion of high sugar foods. Type 2 diabetics demonstrate a greatly reduced incretin induced insulin release response.
This response in hyperglycemic conditions is counterbalanced by the rapid rate of degradation of these incretin hormones by dipeptidyl peptidase IV in normal conditions. Inhibition of dipeptidyl peptidase IV results in longer lifetime of the incretin hormones in the GI tract and thus prolonged stimulation of insulin production. Specific dipeptidyl peptidase inhibitors are actively being explored as drug targets for treating type 2 diabetes and several candidates are actively in clinical trial.
This response in hyperglycemic conditions is counterbalanced by the rapid rate of degradation of these incretin hormones by dipeptidyl peptidase IV in normal conditions. Inhibition of dipeptidyl peptidase IV results in longer lifetime of the incretin hormones in the GI tract and thus prolonged stimulation of insulin production. Specific dipeptidyl peptidase inhibitors are actively being explored as drug targets for treating type 2 diabetes and several candidates are actively in clinical trial.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes.
Green BD, et al.
Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease, 3(3), 159-165 (2006)
A Desk Reference on Enzyme Inhibitors, Receptor Antagonists, Drugs, Toxins, Poisons, Biologics, and Therapeutic Leads.
Purich D.
The Inhibitor Index (2017)
Involvement of the active metabolites in the inhibitory activity of K579 on rat plasma dipeptidyl peptidase IV.
Takasaki K, et al.
European Journal of Pharmacology, 505(1-3), 237-241 (2004)
Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes.
Green B D, et al.
Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease, 3(3), Green-Green (2006)
Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes.
Holst J J, et al.
Diabetes Care, 34(2), S251-S257 (2011)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持